CN114354926A - Detection method of echovirus 9 type antibody - Google Patents
Detection method of echovirus 9 type antibody Download PDFInfo
- Publication number
- CN114354926A CN114354926A CN202210015304.XA CN202210015304A CN114354926A CN 114354926 A CN114354926 A CN 114354926A CN 202210015304 A CN202210015304 A CN 202210015304A CN 114354926 A CN114354926 A CN 114354926A
- Authority
- CN
- China
- Prior art keywords
- echo9
- hole
- plate
- igm
- igg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 25
- 241000709643 Echovirus E9 Species 0.000 title claims description 14
- 108090000790 Enzymes Proteins 0.000 claims abstract description 27
- 102000004190 Enzymes Human genes 0.000 claims abstract description 27
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 210000002966 serum Anatomy 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 25
- 238000005406 washing Methods 0.000 claims description 18
- 238000002965 ELISA Methods 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 16
- 239000013642 negative control Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 241000283707 Capra Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 230000031700 light absorption Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001976 enzyme digestion Methods 0.000 claims description 4
- 239000013641 positive control Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 239000012224 working solution Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 108091081024 Start codon Proteins 0.000 claims description 3
- 101150024766 VP1 gene Proteins 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003593 chromogenic compound Substances 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 235000014304 histidine Nutrition 0.000 claims description 3
- 150000002411 histidines Chemical class 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 239000012460 protein solution Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 239000012089 stop solution Substances 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 238000012795 verification Methods 0.000 claims description 3
- 241000700605 Viruses Species 0.000 abstract description 10
- 206010014599 encephalitis Diseases 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 241001466953 Echovirus Species 0.000 abstract description 3
- 230000004907 flux Effects 0.000 abstract description 3
- 230000002779 inactivation Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000010586 diagram Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 2
- 206010014612 Encephalitis viral Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an echovirus 9-type antibody detection method, which takes ECHO9VP1 recombinant protein as an antigen of an enzyme label plate, breaks through the limitation that the prior enzyme label plate is directly coated by virus strain inactivation as the antigen or the cell is infected by the virus strain to prepare an antigen tablet, and realizes the requirements of high flux and safety in the preparation of the enzyme label antigen plate. The invention is not only beneficial to the clinical treatment of aseptic encephalitis disease, but also plays an important role in the research of early discovery, early intervention and epidemiology of epidemic outbreak caused by ECHO9 and the technical support for guaranteeing the health of people.
Description
Technical Field
The invention relates to the technical field of medical treatment, in particular to an echovirus 9 type antibody detection method.
Background
Aseptic encephalitis outbreaks caused by Echovirus type 9 (ECHO 9) have been reported in the united states, canada, uk, europe, japan, korea, and so on. The incidence of viral encephalitis is high in China, but few viral encephalitis caused by ECHO9 are reported, which may be related to the fact that no effective method for detecting ECHO9 exists. At present, the ECHO9 etiology detection mainly adopts virus culture, serum neutralization test or RT-PCR amplification target gene strip, then gene sequencing is carried out, and Blast comparison is carried out on GeneBank website to determine the type of the ECHO9 virus. The methods have the common defects of time and labor waste, incapability of high-throughput detection, higher requirements on laboratory personnel, instruments and equipment, higher cost and incapability of being carried out in a basic laboratory. Therefore, the establishment of the ECHO9 antibody detection method is not only beneficial to the clinical treatment of aseptic encephalitis disease, but also plays a vital role in the early discovery and early intervention of outbreak epidemic situation and the guarantee of the health of people.
Disclosure of Invention
The invention aims to provide a method for detecting an echovirus type 9 antibody. The invention has the advantages of rapid detection and high accuracy, and can meet the requirements of high throughput and safety in detection.
The technical scheme of the invention is as follows: the detection method of the echovirus 9 type antibody comprises the following steps:
s1: preparation of ECHO9 pET28a-VP1 recombinant plasmid: carrying out rare codon optimization of escherichia coli on the ECHO9VP1 sequence, and re-synthesizing the ECHO9VP1 sequence;
plasmid pET28a + expression reading frame design VP1 gene amplification primers:
an upstream primer: 5'-CATATGGGTAGGGTTGCTGACACAATACG-3', containing NdeI restriction site and initiation codon ATG;
a downstream primer: 5'-CTCGAGTTACACATACACAGCTCCAGATTCTTGG-3', containing XhoI cleavage sites;
carrying out double enzyme digestion on the resynthesized ECHO9VP1 sequence and the plasmid pET28a + prokaryotic expression vector by NdeI and XhoI respectively to obtain an ECHO9 pET28a-VP1 recombinant plasmid;
s2: high-efficiency expression of ECHO9VP1 recombinant protein and verification: the recombinant bacterium induced by IPTG is adopted to efficiently express the ECHO9VP1 recombinant protein, and 6 histidines contained at the N tail end of the protein are utilized to be purified and identified by a nickel column affinity chromatography method, so as to obtain the 37kD ECHO9VP1 recombinant protein;
s3: preparing enzyme-labeled antigen plate by preparing 10 microgram/ml recombinant protein solution with pH9.6 and 0.01mol/L carbonate buffer solution, adding 0.1ml to each hole of 96-hole enzyme-labeled plate, and coating overnight at 4 ℃; washing with 0.05% Tween 20-0.01mol/L PBS for 3 times, sealing with 20% calf serum, and sealing the prepared enzyme-labeled antigen plate in a refrigerator at 4 deg.C;
s4 establishment of the detection method of the ECHO9 IgM/IgG antibody in human serum: 1:20 diluted human serum is used as a primary antibody; 1, using HRP-marked goat anti-human IgM diluted by 5000 or using HRP-marked goat anti-human IgG as a secondary antibody and TMB as a chromogenic substrate, establishing detection ECHO9VP 1-IgM/IgG-ELISAs, and determining the OD value of each hole by using a Bio-Rad enzyme labeling instrument after terminating the reaction: the measurement wavelength is 450nm, and the reference wavelength is 630 nm; if the OD light absorption value of the detected specimen is larger than or equal to the negative control mean value +3SD, the specimen is positive.
In the detection method of the echovirus 9-type antibody, in step S1, T4 ligase is adopted for connection, after the connection, a product is transferred into E.coli DH 5 alpha for culture, and a monoclonal is selected for PCR, enzyme digestion and sequencing identification of recombinant plasmids.
In the detection method of the echovirus type 9 antibody, in step S4, the operation steps for detecting the ECHO9 IgM or IgG antibody in human serum are as follows:
s4.1, setting a negative control 2 hole and a positive control 1 hole in a test, and adding 100 mu L of corresponding liquid into each hole; setting blank contrast 1 hole empty;
s4.2, adding physiological saline or PBS 1:100 mu L of 20 diluted serum sample, vibrating, uniformly mixing, sticking a sealing film, and placing in an incubator at 37 ℃ for 30 minutes;
s4.3, preparing 0.05% Tween 20-0.01mol/L PBS washing liquid for later use;
s4.4, placing the plate washing machine to wash the plate, and repeatedly washing the plate for 5 times;
s4.5, adding an enzyme-labeled working solution, wherein each hole is 100 mu L, and a blank hole is not added, and placing the mixture in an incubator at 37 ℃ for 30 minutes;
s4.6, placing the plate washing machine to wash the plate, and repeatedly washing the plate for 5 times;
s4.7, sucking 100 mu L of TMB into each hole, fully mixing the TMB and the hole uniformly, and placing the mixture at room temperature for developing for 10 minutes;
s4.8, immediately adding 100 mu L of stop solution into each hole, and placing the mixture into an enzyme-linked immunosorbent assay device to determine the wavelength to be 450nm and the reference wavelength to be 630 nm. Adjusting zero by using a blank hole, and reading the OD value of each hole; if the OD light absorption value of the detected specimen is larger than or equal to the negative control mean value +3SD, the specimen is positive.
In the foregoing method for detecting an echovirus type 9 antibody, the determining the result of the operation of detecting an ECHO9 IgM or IgG antibody in human serum includes:
if IgM and IgG antibodies in human serum are negative, ECHO9 is not infected;
ECHO9 IgM positive and IgG negative in human serum, which is ECHO9 infection acute phase;
ECHO9 positive IgM and IgG in human serum is ECHO9 infection recovery period;
ECHO9 IgM negative and IgG positive in human serum are ECHO9 past infection.
Compared with the prior art, the enzyme-labeled plate uses the ECHO9VP1 recombinant protein as the antigen of the enzyme-labeled plate, breaks through the limitation that the prior enzyme-labeled plate is directly coated with the virus strain through inactivation of the virus strain or the virus strain infects cells to prepare the antigen tablet, and meets the requirements of high flux and safety in preparation of the enzyme-labeled antigen plate. The invention coats the expressed and purified ECHO9VP1 recombinant protein on an ELISA plate, optimizes ELISA test conditions, and establishes a method for detecting IgM and IgG in human serum against ECHO9 by an indirect ELISA method. The invention is not only beneficial to the clinical treatment of aseptic encephalitis disease, but also plays a vital role in the early discovery and early intervention of epidemic situation and the guarantee of the health of people.
Drawings
FIG. 1 is a flow chart of the present invention;
FIG. 2 is a schematic diagram of the construction of recombinant plasmid ECHO9 pET28a-VP 1;
FIG. 3 is a schematic diagram showing the restriction enzyme identification of the recombinant plasmid pET28a-VP 1;
FIG. 4 is a diagram showing the identification of purified VP1 protein by Western blot;
FIG. 5 is a schematic diagram of Western blot for identifying VP1 protein rabbit antibody;
FIG. 6 is a diagram illustrating the ELISA method for identifying the rabbit antibody titer of VP1 protein.
Detailed Description
The invention is further illustrated by the following figures and examples, which are not to be construed as limiting the invention.
Example (b): an echovirus 9 type antibody detection method is shown in figure 1 and comprises the following steps:
s1: as shown in FIG. 2, ECHO9 pET28a-VP1 recombinant plasmid was prepared: carrying out rare codon optimization of escherichia coli on an ECHO9VP1 sequence published in GenBank, and re-synthesizing an ECHO9VP1 sequence;
plasmid pET28a + expression reading frame design VP1 gene amplification primers:
an upstream primer: 5'-CATATGGGTAGGGTTGCTGACACAATACG-3', containing NdeI restriction site and initiation codon ATG;
a downstream primer: 5'-CTCGAGTTACACATACACAGCTCCAGATTCTTGG-3', containing XhoI cleavage sites;
the resynthesized ECHO9VP1 sequence and plasmid pET28a + prokaryotic expression vector were double digested with NdeI and XhoI, respectively. The DNA fragment is ligated by using T4 ligase, the ligated product is transferred into E.coli DH 5 alpha for culture, and a single clone is picked for PCR as shown in FIG. 3 (note: 1: DNA marker; 2: NdeI and XhoI double digestion pET28a-VP1), and the recombinant plasmid is identified by digestion and sequencing and is named as pET28a-VP 1.
S2: high-efficiency expression of ECHO9VP1 recombinant protein and verification: the recombinant protein ECHO9VP1 is efficiently expressed by recombinant bacteria induced by IPTG, and the recombinant protein ECHO9VP1 is obtained by purifying and identifying 6 histidines contained at the N-terminal of the protein by a nickel column affinity chromatography, as shown in figure 4 (note 1: protein marker; 2: purified VP1 protein). The polyclonal antibody prepared by immunizing a rabbit with the purified VP1 recombinant protein shows that the polyclonal antibody can specifically bind to VP1 protein, as shown in FIG. 5 (note: 1: protein marker antibody; 2: VP1 protein rabbit antibody). The experimental result of FIG. 5 shows that the purified recombinant protein has better antigenicity and can be used as an indirect ELISA diagnostic antigen.
TABLE 1
The ELISA method for identifying the rabbit antibody titer of the VP1 protein is shown in Table 1 and FIG. 6. The purified VP1 recombinant protein 100 ng/well is coated on an enzyme label plate; rabbit serum polyclonal antibody diluted by 1:1000, 1:5000, 1:10000, 1:50000 and 1:100000 is taken as a first antibody; goat anti-rabbit IgG (H + L) as secondary antibody, and 5% PBS milk as primary antibody for negative control; the positive control used anti-His antibody 6E25ug/ml as the primary antibody. Experiments show that the rabbit serum polyclonal antibody can still be combined with the purified VP1 recombinant protein for color development after being diluted by one hundred thousand times. The result shows that the recombinant VP1 protein has good immunogenicity. Wherein from left to right in FIG. 6, the diluted rabbit serum is 1:1000, 1:5000, 1:10000, 1:50000, 1:100000 in 1-5 wells; 6 wells are negative controls.
S3: preparing enzyme-labeled antigen plate by preparing 10 microgram/ml recombinant protein solution with pH9.6 and 0.01mol/L carbonate buffer solution, adding 0.1ml to each hole of 96-hole enzyme-labeled plate, and coating overnight at 4 ℃; washing with 0.05% Tween 20-0.01mol/L PBS (pH7.4) for 3 times, sealing with 20% calf serum, sealing the prepared enzyme-labeled antigen plate in a refrigerator at 4 deg.C, and storing;
s4 establishment of the detection method of the ECHO9 IgM/IgG antibody in human serum: 1:20 diluted human serum is used as a primary antibody; 1, using HRP-marked goat anti-human IgM diluted by 5000 or using HRP-marked goat anti-human IgG as a secondary antibody and TMB as a chromogenic substrate, establishing detection ECHO9VP 1-IgM/IgG-ELISAs, and determining the OD value of each hole by using a Bio-Rad enzyme labeling instrument after terminating the reaction: the measurement wavelength is 450nm, and the reference wavelength is 630 nm; if the OD light absorption value of the detected specimen is larger than or equal to the negative control mean value +3SD, the specimen is positive.
The procedures for detecting ECHO9 IgM or IgG antibody in human serum are as follows:
s4.1, setting a negative control 2 hole and a positive control 1 hole in a test, and adding 100 mu L of corresponding liquid into each hole; setting blank contrast 1 hole empty;
s4.2, adding physiological saline or PBS 1:100 mu L of 20 diluted serum sample, vibrating, uniformly mixing, sticking a sealing film, and placing in an incubator at 37 ℃ for 30 minutes;
s4.3, preparing 0.05% Tween 20-0.01mol/L PBS (pH7.4) washing solution for later use;
s4.4, placing the plate washing machine to wash the plate, and repeatedly washing the plate for 5 times;
s4.5, adding enzyme-labeled working solution (HRP-labeled goat anti-human IgM or IgG), adding 100 mu L of enzyme-labeled working solution into each hole, not adding blank holes, and placing the holes in an incubator at 37 ℃ for 30 minutes;
s4.6, placing the plate washing machine to wash the plate, and repeatedly washing the plate for 5 times;
s4.7, sucking 100 mu L of TMB into each hole, fully mixing the TMB and the hole uniformly, and placing the mixture at room temperature for developing for 10 minutes;
s4.8, immediately adding 100 mu L of stop solution into each hole, and placing the mixture into an enzyme-linked immunosorbent assay device to determine the wavelength to be 450nm and the reference wavelength to be 630 nm. Adjusting zero by using a blank hole, and reading the OD value of each hole; if the OD light absorption value of the detected specimen is larger than or equal to the negative control mean value +3SD, the specimen is positive.
The judgment of the result of the detection operation includes:
if IgM and IgG antibodies in human serum are negative, ECHO9 is not infected;
ECHO9 IgM positive and IgG negative in human serum, which is ECHO9 infection acute phase;
ECHO9 positive IgM and IgG in human serum is ECHO9 infection recovery period;
ECHO9 IgM negative and IgG positive in human serum are ECHO9 past infection.
The invention coats the expressed and purified ECHO9VP1 recombinant protein on an ELISA plate, optimizes ELISA test conditions, and establishes a method for detecting IgM and IgG in human serum against ECHO9 by an indirect ELISA method. The results of the ECHO-9 epidemic positive serum detected by the ELISAs method established by the invention are consistent with those of the German Severe echovirus detection kit. By using the ELISA method established by the invention, 176 parts of serum of febrile children under the less than fourteen years old with negative rubella and measles IgM antibody detection in Hangzhou areas and 240 parts of serum of physical examination children are screened by ECHO 9. And comparing the result with a German Severe Exxon virus detection kit, and finding that the detection positive rate of the method is close to that of the German Severe kit. The present invention also found that the antibody positivity rates for febrile children were comparable with the two methods, but the antibody ECHO9 positivity rates for healthy children were more than doubled. After comparison of the two methods, no statistical difference was found for the febrile children, 2 ═ 1.647 and P ═ 0.199. But for healthy children, 2 ═ 5.47, P ═ 0.019; the two methods are statistically different.
In conclusion, the ECHO9VP1 recombinant protein is used as the antigen of the enzyme label plate, the limitation that the prior enzyme label plate is directly coated with the virus strain through inactivation of the virus strain or the virus strain infects cells to prepare the antigen tablet is broken through, and the requirements of high flux and safety in preparation of the enzyme label plate are met. The invention is not only beneficial to the clinical treatment of aseptic encephalitis disease, but also plays an important role in the research of early discovery, early intervention and epidemiology of epidemic outbreak caused by ECHO9 and the technical support for guaranteeing the health of people.
Claims (4)
1. A method for detecting an echovirus type 9 antibody, which is characterized by comprising the following steps: the method comprises the following steps:
s1: preparation of ECHO9 pET28a-VP1 recombinant plasmid: carrying out rare codon optimization of escherichia coli on the ECHO9VP1 sequence, and re-synthesizing the ECHO9VP1 sequence;
plasmid pET28a + expression reading frame design VP1 gene amplification primers:
an upstream primer: 5'-CATATGGGTAGGGTTGCTGACACAATACG-3', containing NdeI restriction site and initiation codon ATG;
a downstream primer: 5'-CTCGAGTTACACATACACAGCTCCAGATTCTTGG-3', containing XhoI cleavage sites;
carrying out double enzyme digestion on the resynthesized ECHO9VP1 sequence and the plasmid pET28a + prokaryotic expression vector by NdeI and XhoI respectively to obtain an ECHO9 pET28a-VP1 recombinant plasmid;
s2: high-efficiency expression of ECHO9VP1 recombinant protein and verification: the ECHO9VP1 recombinant protein is efficiently expressed by recombinant bacteria induced by IPTG, and the protein is purified and identified by a nickel column affinity chromatography method by utilizing 6 histidines contained at the N tail end of the protein, so as to obtain the 37kD ECHO9VP1 recombinant protein;
s3: preparing enzyme-labeled antigen plate by preparing 10 microgram/ml recombinant protein solution with pH9.6 and 0.01mol/L carbonate buffer solution, adding 0.1ml to each hole of 96-hole enzyme-labeled plate, and coating overnight at 4 ℃; washing with 0.05% Tween 20-0.01mol/L PBS for 3 times, sealing with 20% calf serum, and sealing the prepared enzyme-labeled antigen plate in a refrigerator at 4 deg.C;
s4 establishment of the detection method of the ECHO9 IgM/IgG antibody in human serum: 1:20 diluted human serum is used as a primary antibody; 1, using HRP-marked goat anti-human IgM diluted by 5000 or using HRP-marked goat anti-human IgG as a secondary antibody and TMB as a chromogenic substrate, establishing detection ECHO9VP 1-IgM/IgG-ELISAs, and determining the OD value of each hole by using a Bio-Rad enzyme labeling instrument after terminating the reaction: the measurement wavelength is 450nm, and the reference wavelength is 630 nm; if the OD light absorption value of the detected specimen is larger than or equal to the negative control mean value +3SD, the specimen is positive.
2. The method for detecting an echovirus type 9 antibody according to claim 1, wherein: in step S1, T4 ligase is used for ligation, the product is transferred to e.coli DH 5 α for culture, and a single clone is selected for PCR, enzyme digestion and sequencing to identify the recombinant plasmid.
3. The method for detecting an echovirus type 9 antibody according to claim 1, wherein: in step S4, the procedures for detecting ECHO9 IgM or IgG antibodies in human serum are as follows:
s4.1, setting a negative control 2 hole and a positive control 1 hole in a test, and adding 100 mu L of corresponding liquid into each hole; setting blank contrast 1 hole empty;
s4.2, adding physiological saline or PBS 1:100 mu L of 20 diluted serum sample, vibrating, uniformly mixing, sticking a sealing film, and placing in an incubator at 37 ℃ for 30 minutes;
s4.3, preparing 0.05% Tween 20-0.01mol/L PBS washing liquid for later use;
s4.4, placing the plate washing machine to wash the plate, and repeatedly washing the plate for 5 times;
s4.5, adding an enzyme-labeled working solution, wherein each hole is 100 mu L, and a blank hole is not added, and placing the mixture in an incubator at 37 ℃ for 30 minutes;
s4.6, placing the plate washing machine to wash the plate, and repeatedly washing the plate for 5 times;
s4.7, sucking 100 mu L of TMB into each hole, fully mixing the TMB and the hole uniformly, and placing the mixture at room temperature for developing for 10 minutes;
s4.8, immediately adding 100 mu L of stop solution into each hole, and placing the mixture into an enzyme-linked immunosorbent assay device to determine the wavelength to be 450nm and the reference wavelength to be 630 nm. Adjusting zero by using a blank hole, and reading the OD value of each hole; if the OD light absorption value of the detected specimen is larger than or equal to the negative control mean value +3SD, the specimen is positive.
4. The method for detecting an echovirus type 9 antibody according to claim 3, wherein: the judgment of the result of the ECHO9 IgM or IgG antibody detection operation in human serum comprises the following steps:
if IgM and IgG antibodies in human serum are negative, ECHO9 is not infected;
ECHO9 IgM positive and IgG negative in human serum, which is ECHO9 infection acute phase;
ECHO9 positive IgM and IgG in human serum is ECHO9 infection recovery period;
ECHO9 IgM negative and IgG positive in human serum are ECHO9 past infection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210015304.XA CN114354926A (en) | 2022-01-07 | 2022-01-07 | Detection method of echovirus 9 type antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210015304.XA CN114354926A (en) | 2022-01-07 | 2022-01-07 | Detection method of echovirus 9 type antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114354926A true CN114354926A (en) | 2022-04-15 |
Family
ID=81106644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210015304.XA Pending CN114354926A (en) | 2022-01-07 | 2022-01-07 | Detection method of echovirus 9 type antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114354926A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017107974A1 (en) * | 2015-12-23 | 2017-06-29 | 中国人民解放军第二军医大学 | Detection test kit for serum psmd4 proteins and detection method and application thereof |
-
2022
- 2022-01-07 CN CN202210015304.XA patent/CN114354926A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017107974A1 (en) * | 2015-12-23 | 2017-06-29 | 中国人民解放军第二军医大学 | Detection test kit for serum psmd4 proteins and detection method and application thereof |
Non-Patent Citations (1)
Title |
---|
邱晓枫;黄志成;张国忠;濮小英;潘劲草;王咪咪;: "埃可病毒9型VP1蛋白的原核表达及多克隆抗体制备", 中国卫生检验杂志, no. 07, 10 April 2015 (2015-04-10), pages 951 - 965 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tan et al. | Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers | |
Meyer et al. | Serological assays for emerging coronaviruses: challenges and pitfalls | |
Che et al. | Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome | |
Midgley et al. | An in-depth analysis of original antigenic sin in dengue virus infection | |
KR100847586B1 (en) | Method for assaying hepatitis c virus | |
CN111925436B (en) | Monoclonal antibody of African swine fever virus P30 protein and application thereof | |
CN112505330B (en) | Kit for detecting novel coronavirus based on fusion protein of nucleocapsid protein | |
US20230235028A1 (en) | Antibody against sars-cov-2, method for detecting sars-cov-2 using antibody and kit containing antibody | |
CN104215761B (en) | Detect the kit of anti-GP73 antibody in serum | |
WO2012163263A1 (en) | Reagents and methods for prrsv detection | |
JP6080850B2 (en) | Improved vaccine diagnostics | |
Ji et al. | An improved indirect ELISA for specific detection of antibodies against classical swine fever virus based on structurally designed E2 protein expressed in suspension mammalian cells | |
CN114736290A (en) | Nano antibody capable of identifying porcine pseudorabies virus with high accuracy and sensitivity, preparation method and application | |
US20230375548A1 (en) | Indirect enzyme-linked immunosorbent assay detection kit based on p30 protein and p22 protein of african swine fever virus | |
Pan et al. | Application of truncated immunodominant polypeptide from hepatitis E virus (HEV) ORF2 in an assay to exclude nonspecific binding in detecting anti-HEV immunoglobulin M | |
WO2021170090A1 (en) | Sars-cov-2 virus detection method and detection kit | |
CN114354926A (en) | Detection method of echovirus 9 type antibody | |
Zhang et al. | Development of a potential diagnostic monoclonal antibody against capsid spike protein VP27 of the novel goose astrovirus | |
JP7489228B2 (en) | SARS-CoV-2 derived nucleocapsid fragment and method and kit for detecting anti-SARS-CoV-2 antibodies using said fragment | |
US20230331783A1 (en) | HCV Recombinant Antigen and Mutant thereof | |
Jun et al. | Expression and characterization of the soluble form of recombinant mature HSV-2 glycoprotein G for use in anti-HSV-2 IgG serodiagnostic immunoassay | |
Cai et al. | Detection of asymptomatic antigenemia in pigs infected by porcine reproductive and respiratory syndrome virus (PRRSV) by a novel capture immunoassay with monoclonal antibodies against the nucleocapsid protein of PRRSV | |
JP4619580B2 (en) | Antibody immunoassay by antibody capture method | |
CN112159797B (en) | Hybridoma cell strain 3G 71B 10, anti-GII.4 type norovirus P protein monoclonal antibody and application | |
JP5805943B2 (en) | Method for producing pertussis Fim3 and method for detecting pertussis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |